RECIST (Response Evaluation Criteria in Solid Tumors) guidelines were introduced over twenty years ago to provide a standard for evaluating tumor response, with the goal of maintaining consistency at sites and across sites as well as limiting any site bias. 

With the introduction of intratumoral (IT) immunotherapies, IT immunotherapy RECIST (itRECIST) is proposed to capture data and assess local and systemic responses in a standardized fashion for clinical trials involving these therapies.


CS thumbnail_itRECIST tumor modalityOvercoming Methodology Hurdles
Veristat helped a sponsor write the protocol for a novel treatment that injects engineered exosomes into solid tumors. The application of a set of nuanced response criteria required information collected from injected and non-injected lesions to determine a tumor’s response to the treatment.


itRECIST criteria were used in this scenario to measure changes in tumor size; but as this is a new method for tracking a novel treatment, protocols had to be developed.


Access the Full-Length Case Study

Read the case study to learn more about how our team defined the appropriate methodology for collection and data analysis in this largely untested area of clinical development.





Explore Related Services:



1 min read

Biotechgate Digital Partnering 2023

Meet Veristat  during Biotechgate Digital PartneringNovember 27- December 1  

With nearly 30 years of experience in...

1 min read

DTRA 2023

Meet Veristat in Boston at DTRA  

With nearly 30 years of experience in clinical trial planning and execution for...